Tufts Survey Paints Optimistic Outlook for Personalized Rx in Drug Development
November 21, 2010
Tufts Survey Paints Optimistic Outlook for Personalized Rx in Drug Development
A survey by the Tufts Center for the Study of Drug Development reveals that genomically targeted strategies and companion diagnostics are steadily gaining prominence among pharmaceutical companies' pipelines.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With New BRCA Testing Options, Patient Groups Advise Women to Speak to Genetics Expert, Share Reports
June 19, 2013 / Pharmacogenomics Reporter - Cancer Genetics to Provide Testing for Roche Servicios Oncology Program
August 2, 2012 / GenomeWeb Daily News - Ontario Genomics Institute Invests in New Cancer Dx Firm
March 9, 2012 / GenomeWeb Daily News - Clinical Applications of Next-Gen Sequencing Debut at AGBT
February 22, 2012 / Clinical Sequencing News - GE's Clarient to be Key Beneficiary of $1B Bid to Bolster Molecular Dx Presence in Oncology
September 21, 2011 / Pharmacogenomics Reporter